High-priority drug-drug interactions for use in electronic health records

OBJECTIVE To develop a set of high-severity, clinically significant drug-drug interactions (DDIs) for use in electronic health records (EHRs). METHODS A panel of experts was convened with the goal of identifying critical DDIs that should be used for generating medication-related decision support alerts in all EHRs. Panelists included medication knowledge base vendors, EHR vendors, in-house knowledge base developers from academic medical centers, and both federal and private agencies involved in the regulation of medication use. Candidate DDIs were assessed by the panel based on the consequence of the interaction, severity levels assigned to them across various medication knowledge bases, availability of therapeutic alternatives, monitoring/management options, predisposing factors, and the probability of the interaction based on the strength of evidence available in the literature. RESULTS Of 31 DDIs considered to be high risk, the panel approved a final list of 15 interactions. Panelists agreed that this list represented drugs that are contraindicated for concurrent use, though it does not necessarily represent a complete list of all such interacting drug pairs. For other drug interactions, severity may depend on additional factors, such as patient conditions or timing of co-administration. DISCUSSION The panel provided recommendations on the creation, maintenance, and implementation of a central repository of high severity interactions. CONCLUSIONS A set of highly clinically significant drug-drug interactions was identified, for which warnings should be generated in all EHRs. The panel highlighted the complexity of issues surrounding development and implementation of such a list.

[1]  Diane L. Seger,et al.  Application of Information Technology: Improving Acceptance of Computerized Prescribing Alerts in Ambulatory Care , 2006, J. Am. Medical Informatics Assoc..

[2]  Roger B. Davis,et al.  Overrides of medication alerts in ambulatory care. , 2009, Archives of internal medicine.

[3]  Olivier Bodenreider,et al.  Investigating drug classes in biomedical terminologies from the perspective of clinical decision support. , 2010, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[4]  Robyn Tamblyn,et al.  Reasons for Physician Non-Adherence to Electronic Drug Alerts , 2004, MedInfo.

[5]  Janette M Carpenter,et al.  The Top 100 Drug Interactions: A Guide to Patient Management , 2002 .

[6]  Paul R Dexter,et al.  Computerized Decision Support to Reduce Potentially Inappropriate Prescribing to Older Emergency Department Patients: A Randomized, Controlled Trial , 2009, Journal of the American Geriatrics Society.

[7]  Adam Wright,et al.  The state of the art in clinical knowledge management: An inventory of tools and techniques , 2010, Int. J. Medical Informatics.

[8]  Thomas H. Payne,et al.  Review Paper: Medication-related Clinical Decision Support in Computerized Provider Order Entry Systems: A Review , 2007, J. Am. Medical Informatics Assoc..

[9]  Marc Berg,et al.  Overriding of drug safety alerts in computerized physician order entry. , 2006, Journal of the American Medical Informatics Association : JAMIA.

[10]  D. Bates,et al.  Critical Drug-Drug Interactions for Use in Electronic Health Records Systems With Computerized Physician Order Entry: Review of Leading Approaches , 2011, Journal of patient safety.

[11]  Ira J. Kalet,et al.  Computing with evidence: Part II: An evidential approach to predicting metabolic drug-drug interactions , 2009, J. Biomed. Informatics.

[12]  Amy J Grizzle,et al.  Concordance of severity ratings provided in four drug interaction compendia. , 2004, Journal of the American Pharmacists Association : JAPhA.

[13]  D. Bates,et al.  Towards Meaningful Medication-Related Clinical Decision Support: Recommendations for an Initial Implementation , 2011, Applied Clinical Informatics.

[14]  A. Vitry,et al.  Comparative assessment of four drug interaction compendia. , 2007, British journal of clinical pharmacology.

[15]  R. Lipton,et al.  Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. , 2005, Journal of the American Pharmacists Association : JAPhA.

[16]  Yu Ko,et al.  Clinically Significant Drug–Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: Profiling and Comparison of Two Drug Compendia , 2008, The Annals of pharmacotherapy.

[17]  P. Aspden,et al.  Preventing Medication Errors , 2007 .

[18]  J. Lightwood,et al.  Black Box Warning Contraindicated Comedications: Concordance Among Three Major Drug Interaction Screening Programs , 2010, The Annals of pharmacotherapy.

[19]  Amanda L Golbeck,et al.  The Potential for Clinically Significant Drug-Drug Interactions Involving the CYP 2D6 System: Effects with Fluoxetine and Paroxetine versus Sertraline , 2007, Journal of psychiatric practice.

[20]  T K Hazlet,et al.  ORCA: OpeRational ClassificAtion of drug interactions. , 2001, Journal of the American Pharmaceutical Association.

[21]  John R. Horn,et al.  The Top 100 Drug Interactions: A Guide to Patient Management, 2010 Edition , 2010 .

[22]  Edward P. Armstrong,et al.  Identification of serious drug-drug interactions: results of the partnership to prevent drug-drug interactions. , 2004, Journal of the American Pharmacists Association : JAPhA.

[23]  Diane L. Seger,et al.  Viewpoint Paper: Tiering Drug-Drug Interaction Alerts by Severity Increases Compliance Rates , 2009, J. Am. Medical Informatics Assoc..

[24]  Robyn Tamblyn,et al.  A randomized trial of the effectiveness of on-demand versus computer-triggered drug decision support in primary care. , 2008, Journal of the American Medical Informatics Association : JAMIA.

[25]  E. Olvey,et al.  Comparison of Critical Drug–Drug Interaction Listings: The Department of Veterans Affairs Medical System and Standard Reference Compendia , 2010, Clinical pharmacology and therapeutics.

[26]  Christopher D Miller,et al.  Predictors of Clinically Significant Drug-Drug Interactions Among Patients Treated with Nonnucleoside Reverse Transcriptase Inhibitor–, Protease Inhibitor–, and Raltegravir-Based Antiretroviral Regimens , 2011, The Annals of pharmacotherapy.